Governance Sarepta Therapeutics, Inc.

SRPT

US8036071004

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 02:30:00 06/12/2025 am IST			5-day change	1st Jan Change
22.26 ^USD	-2.45%		+6.25%	-81.69%

25/11	Sarepta Therapeutics, Inc. Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of Elevidys Gene Therapy for Non-Ambulant Individuals with Duchenne	CI
25/11	Sarepta Therapeutics Receives FDA Approval for Dosing Levels for Elevidys Study to Treat Duchenne Muscular Dystrophy	MT

Executive Committee: Sarepta Therapeutics, Inc.

Manager

Positions heldSince

Douglas Ingram

62 year

Chief Executive Officer

26/06/2017

Ian Estepan

49 year

Chief Operating Officer	16/07/2025
President	16/07/2025

Louise Rodino-Klapac

47 year

Chief Tech/Sci/R&D Officer

14/12/2020

Alison Nasisi

Human Resources Officer

01/10/2021

Cristin Rothfuss

57 year

General Counsel

01/11/2024

Ryan Wong

46 year

Director of Finance/CFO

16/07/2025

Composition of the Board of Directors: Sarepta Therapeutics, Inc.

Director

CommitteesSince

M. Wilsey

72 year

Audit Committee Chair
Audit Committee	19/06/2019
Governance Committee	19/06/2019
Nominating Committee	19/06/2019

Deirdre Connelly

64 year

Compensation Committee	26/03/2020
Governance Committee Chair	26/03/2020
Nominating Committee Chair	26/03/2020
Audit Committee	26/03/2020
Executive Committee
Governance Committee	10/08/2016
Compensation Committee Chair	26/05/2016
Finance Committee	26/03/2020

Kathryn Boor

66 year

Compensation Committee	02/06/2022
Governance Committee Chair	01/01/2019
Nominating Committee Chair	01/01/2019
Governance Committee	02/06/2022
Nominating Committee	02/06/2022

Claude Nicaise

72 year

Compensation Committee Chair	09/09/2024
Compensation Committee	01/02/2021
Governance Committee	09/09/2024
Nominating Committee	09/09/2024
Audit Committee Chair

Richard Barry

66 year

Audit Committee	02/06/2015
Compensation Committee	02/06/2015
Governance Committee Chair	02/06/2015
Nominating Committee Chair	02/06/2015

Hans Lennart Rudolf Wigzell

86 year

Governance Committee	05/05/2015
Nominating Committee	05/05/2015

Stephen Mayo

63 year

Audit Committee

12/07/2022

Michael Chambers

50 year

Director/Board Member	02/06/2022
Independent Dir/Board Member	02/06/2022

Latest Appointments: Sarepta Therapeutics, Inc.

03/11	Kalaris Therapeutics, Inc. Announces Executive Changes, Effective from November 3, 2025	CI
06/10	KalVista Pharmaceuticals Names Bilal Arif as COO, Linea Aspesi as Chief People Officer	MT
03/09	Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel	CI
14/08	Sarepta Therapeutics, Inc. Announces End of Employment for Bilal Arif as Executive Vice President, Chief Technical Operations Officer, Effective September 16, 2025	CI
12/08	Vinay Prasad returns to role as top vaccine regulator at FDA days after leaving US agency	RE
10/08	Vinay Prasad returns to role as top vaccine regulator at FDA days after leaving US agency	RE
30/07	US FDA's top vaccine official Vinay Prasad leaves agency after 3 months	RE

More news

Former Officers and Directors: Sarepta Therapeutics, Inc.

Insider

Positions held

SinceUntil

Jayant Aphale

Corporate Officer/Principal

14/12/2011

01/01/2024

Mary Gray

Director/Board Member	11/12/2018	02/06/2022
Independent Dir/Board Member	11/12/2018	02/06/2022

Gilmore O’Neill

Chief Tech/Sci/R&D Officer

07/06/2018

17/11/2021

Joan Nickerson

Human Resources Officer

01/10/2016

01/04/2021

TY Howton

General Counsel	05/11/2012	-
Corporate Secretary	05/11/2012	14/12/2020

Alexander Cumbo

Corporate Officer/Principal

01/01/2013

01/10/2020

Sandy Mahatme

Director of Finance/CFO

05/11/2012

10/07/2020

Michael Bonney

Director/Board Member	05/12/2017	18/03/2020
Independent Dir/Board Member	05/12/2017	18/03/2020

Guriqbal S. Basi

Chief Tech/Sci/R&D Officer

25/09/2017

01/09/2018

Gary Charbonneau

General Counsel

01/05/2018

Shamim Ruff

General Counsel

01/01/2013

01/05/2018

Catherine Stehman-Breen

Chief Tech/Sci/R&D Officer

04/04/2017

01/12/2017

Edward Kaye

Director/Board Member	20/09/2016	01/08/2017
Chief Executive Officer	01/04/2015	01/07/2017
Chief Tech/Sci/R&D Officer	01/06/2011	01/03/2017
President	20/09/2016	01/07/2017

Jean-Paul Kress

Director/Board Member	30/09/2015	06/06/2017
Independent Dir/Board Member	30/09/2015	06/06/2017

Timothy Kelly

Corporate Officer/Principal

01/01/2017

01/05/2017

Joan Wood

Human Resources Officer

01/04/2015

01/03/2017

Ben Price

Director/Board Member	30/10/2007	01/01/2016
Independent Dir/Board Member	30/10/2007	01/01/2016

Gavin Malenfant

Chief Operating Officer

01/05/2015

01/01/2016

William Goolsbee

Director/Board Member	30/07/2014	01/01/2016
Chairman	30/10/2007	30/07/2014
Independent Dir/Board Member	30/10/2007	01/01/2016

John C. Hodgman

Director/Board Member	01/03/2004	01/06/2015
Chairman	30/07/2014	16/04/2015
Independent Dir/Board Member	01/03/2004	01/06/2015

Christopher Garabedian

Director/Board Member	11/06/2010	01/04/2015
Chief Executive Officer	11/01/2011	01/04/2015
Director of Finance/CFO	29/07/2011	05/11/2012
President	11/01/2011	01/04/2015

Stephan Toutain

Corporate Officer/Principal

01/01/2014

01/01/2015

Arthur M. Krieg

Chief Tech/Sci/R&D Officer

09/01/2014

22/07/2014

Erin S. Cox

Investor Relations Contact

01/08/2011

01/05/2014

Nancy M. Wyant

Chief Tech/Sci/R&D Officer

01/01/2013

01/05/2014

Kathryn Haviland

Corporate Officer/Principal

01/06/2012

01/04/2014

Marco A. Passini

Corporate Officer/Principal

01/01/2017

Anthony Martgnetti

Comptroller/Controller/Auditor

01/10/2013

04/10/2013

Michael Jacobsen

Comptroller/Controller/Auditor	08/09/2011	-
Director of Finance/CFO	09/09/2011	15/11/2011
Corporate Officer/Principal	08/09/2011	08/09/2011
Corporate Secretary	07/09/2011	22/04/2013

Peter S. Linsley

Chief Tech/Sci/R&D Officer

01/05/2011

01/06/2012

Effie Toshav

General Counsel	10/01/2011	24/02/2012
Corporate Secretary	10/01/2011	24/02/2012

Patrick L. Iversen

Chief Tech/Sci/R&D Officer	18/02/2011	01/01/2012
Corporate Officer/Principal	01/01/1997	18/02/2011

Melinda Miles

Comptroller/Controller/Auditor

29/07/2011

06/09/2011

J. Boyle

Comptroller/Controller/Auditor	07/07/2010	24/07/2011
Director of Finance/CFO	18/08/2008	24/07/2011
President	22/04/2010	11/01/2011
Corporate Secretary	22/04/2010	24/07/2011

Stephen Shrewsbury

Chief Tech/Sci/R&D Officer	01/02/2009	20/06/2011
General Counsel	01/02/2009	20/06/2011

Paul Medeiros

Corporate Officer/Principal

19/05/2009

01/06/2011

Graham Johnson

Chief Tech/Sci/R&D Officer

06/09/2010

13/05/2011

Michael D. Casey

Chairman

01/05/2006

07/06/2010

Christopher Henney

Director/Board Member

01/04/2009

01/06/2010

Anthony Chase

Director/Board Member	22/04/2010	-
Independent Dir/Board Member	21/04/2010	-

K. Michael Forrest

Director/Board Member	01/03/2005	21/04/2010
Chief Executive Officer	28/03/2007	21/04/2010

Leslie Hudson

Chief Executive Officer	08/02/2008	20/04/2010
Chief Operating Officer	11/02/2008	20/04/2010
President	11/02/2008	20/04/2010

Jacqueline A. Dombroski

General Counsel

16/02/2010

John W. Fara

Director/Board Member

01/05/2000

31/03/2009

Peter D. O'Hanley

Chief Tech/Sci/R&D Officer	01/03/2004	09/01/2009
General Counsel	01/03/2004	09/01/2009

Gunnar J. Hanson

Corporate Officer/Principal

01/01/2009

Alan P. Timmins

Chief Operating Officer	01/01/1992	18/09/2008
President	01/01/1992	18/09/2008

Shirley J. Leow

Chief Tech/Sci/R&D Officer	01/08/2008	15/11/2011
Corporate Officer/Principal	15/11/2011	-

Ryszard Kole

Corporate Officer/Principal

10/04/2008

Jack L. Bowman

Chairman

01/03/2004

10/03/2008

James Hicks

Director/Board Member

01/01/1997

29/10/2007

Denis Burger

Chief Executive Officer	01/01/1996	27/03/2007
Chairman	01/01/1996	27/03/2007

Joseph B. Horn

Corporate Officer/Principal

01/01/2005

R. Ray Cummings

Corporate Officer/Principal

01/04/2004

Janet Rose Christensen

General Counsel

01/01/2003

David H. Mason

General Counsel

01/01/2000

01/01/2003

Mark M. Webber

Chief Administrative Officer

01/10/1997

Dwight D. Weller

Corporate Officer/Principal

01/01/1991

Kara Boniface

Corporate Officer/Principal

Joseph Rubinfeld

Director/Board Member

Raymond W. Ruddon

Director/Board Member

David Walsey

Public Communications Contact

Michael W. Dochterman

Director/Board Member	-	19/05/2009
Chairman	19/05/2009	-

Sarah J. Bard

Corporate Officer/Principal

Julie Rathbun

Public Communications Contact

Jim Baker

Public Communications Contact

Michael Hubbard

Public Communications Contact

Age distribution of managers

Parity Men Women

Male	13
Female	3

Of which Executive Committee

Male	4
Female	2

Of which Directors

Male	7
Female	1

Revisions

Révisions CA 1 an

Révisions CA 4 mois

Révisions CA 1 mois

Révisions BNA 1 an

Révisions BNA 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Controverses sur les droits de l'Homme

Controverses Subventions fiscales

Conforme à la finance Islamique

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.

Employees

1,372

Sector

Pharmaceuticals

Calendar

03/03 - Q4 2025 Earnings Release (Projected)

More about the company